Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00580827
Other study ID # 9811010624
Secondary ID R01DA013441
Status Completed
Phase N/A
First received
Last updated
Start date September 2003

Study information

Verified date March 2020
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This 18-week, randomized, double blind clinical trial provided treatment for 160 cocaine-dependent opioid addicts, aged 18-65 years. Participants were stabilized on LAAM maintenance during the first 4 weeks and cocaine use was assessed; participants were then stratified by level of cocaine use and randomly assigned to receive one of the following: placebo disulfiram (0 mg/day), disulfiram at 62.5 mg/day, disulfiram at 125 mg/day, or disulfiram at 250 mg/day. During induction onto LAAM, participants were administered increasing doses of LAAM plus placebo disulfiram on a thrice-weekly basis until maintenance doses of LAAM are attained. At the beginning of week 5, participants received LAAM plus disulfiram or placebo disulfiram according to their randomized assignments, and were maintained on these agents through week 16. At the end of the study, participants underwent detoxification from LAAM and active/placebo medication over a 4- to 6-week period. All participants received weekly 1-hour psychotherapy (Cognitive Behavioral Treatment) with experienced clinicians specifically trained to deliver the therapy and who received ongoing supervision. The primary outcomes were retention and reduction in opioid and cocaine use, as assessed by self-report and confirmed by thrice-weekly urinalyses. Secondary outcomes included reductions in other illicit drug and alcohol use, as well as improvements in psychosocial functioning.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date
Est. primary completion date March 2004
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Between the ages of 18-65 years.

- Are not currently enrolled in treatment.

- Participants must demonstrate opioid dependence, as evidenced by documentation of prior opioid agonist maintenance and/or have signs of withdrawal upon administration of naloxone (<0.8 mg, i.m.), and an opioid-positive urine screen.

- Participants also must be current users of cocaine with self-reported use of > 7 gm during the preceding 12 months, self-reported use of > 1 time/week in at least one month preceding study entry, and cocaine-positive urine screen.

- Participants must fulfill DSM-IV criteria for opioid and cocaine dependence.

Exclusion Criteria:

- current diagnosis of other drug or alcohol physical dependence (other than opiates, cocaine or tobacco)

- significant medical conditions such as abnormal liver function (with laboratory findings greater than three times normal).

- active hepatitis; hypertension; a current cardiac condition or high risk of cardiovascular disease; seizure disorders; or another significant underlying medical condition which would contraindicate disulfiram or LAAM treatment.

- meets DSM-IV psychiatric classifications for schizophrenia, bipolar disorder, or other psychotic disorders; exhibiting current suicidality or homicidality; current use of a prescribed psychotropic medication that cannot be discontinued.

- pregnancy.

Study Design


Intervention

Drug:
Placebo
Matched placebo.
Disulfiram
disulfiram at 62.5 mg/day for 12 weeks.
Disulfiram
Disulfiram at 125 mg/day for 12 weeks.
Disulfiram
disulfiram at 250 mg/day for 12 weeks.

Locations

Country Name City State
United States West Haven VA West Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reductions in cocaine use as measured by urine toxicology and self-report 14 weeks
Secondary Predictors of treatment efficacy using DBH genotyping for disulfiram will be tested. 14 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Completed NCT01690546 - Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence Phase 2
Completed NCT01389167 - Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Phase 3
Completed NCT01442493 - Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment N/A
Completed NCT01182402 - Electronic Compliance Monitoring in Opioid Substitution Treatment N/A
Completed NCT00987961 - Linking Hospitalized Injection Drug Users to Buprenorphine Phase 3
Completed NCT00634803 - Clinical Trial of Integrated Treatment for Pain and Opioid Dependence Phase 1/Phase 2
Completed NCT00757744 - Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China Phase 3
Completed NCT00539123 - Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia N/A
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Completed NCT00566969 - Cocaine Withdrawal and Pharmacotherapy Response N/A
Recruiting NCT00241930 - Integrating Buprenorphine Into HIV Treatment Phase 4
Completed NCT00218621 - The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Phase 2
Completed NCT00406484 - Brief Introductory Therapy for Opioid Dependence Phase 2
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT01393392 - Developing a Smoking Cessation Intervention for Methadone Maintained Smokers Phase 1
Completed NCT01416584 - A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment N/A
Recruiting NCT00439049 - Substance Abuse Pre-Treatment Screening Study
Withdrawn NCT00398008 - HIV Risk Reduction and Drug Abuse Treatment in Iran Phase 2
Completed NCT00622596 - Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance N/A